Phase II Study of the Optimal Scheme of Administration of Pazopanib in Thyroid Carcinoma

Inclusion Criteria: * Age ≥ 18 years old, * Histologically confirmed diagnosis of differentiated thyroid cancer (papillary, follicular and poorly differentiated) * Archival tumor sample available. It will be provided for all subjects, for biomarker analysis before and/or during study treatment. * Patients must have been treated with therapeutic RAI. Patients may have received prior treatment with either 1 line of chemotherapy and/or up to 1 Tyrosine Kinase Inhibitor, * Resistance to therapeutic radioiodine (RAI) (for DTC) as demonstrated at least by one of the following: * Absence of iodine uptake in at least one target lesion on a post-therapy radioactive iodine scan, * Presence of a target lesion after a cumulative radio-iodine activity of at least 600 mCi, * Patient with uptake who have RAI treatment of at least 100 mCi within the last 12 months and have disease progression, * Documented progression as per RECIST 1.1 based on 2 consecutives imaging performed within the last 12 months, * Measurable disease according to RECIST version 1.1, * Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1, * Adequate organ system function defined as the following: Hematology: * Absolute Neutrophils Count (ANC) ≥ 1.5 Gi/L * Hemoglobin ≥ 9 g/dL (5.6µM) (transfusion is not allowed within 7 days of screening assessments) * Platelets ≥ 100 Gi/L * Prothrombin Time (PT) ≤ 1.2 x ULN or International Normalized Ratio (INR) ≤ 1.2 Subjects receiving anticoagulant therap…